摘要
目的:观察雷莫司琼在介入术前给药预防由顺铂、表阿霉素等引起的胃肠反应的疗效及其不良反应。方法:恶性肿瘤患者156例,随机分成两组:雷莫司琼和格拉司琼组各78例。入选病例为具备介入动脉化疗或(和)栓塞治疗适应证且化疗方案中均含有顺铂≥50mg/m^2或(和)阿霉素≥40mg/m^2(吡喃阿霉素≥40mg/m^2,表阿霉素≥80mg/m^2)化疗药物。两组分别于化疗前15～30min取雷莫司琼注射液0.3mg,格拉司琼3mg加入地塞米松10mg静脉推注。观察患者第1～3天食欲不振、恶心、呕吐等情况,并观察两种止吐药物的不良反应。结果:化疗后0～6h,0～12h,0～18h和0～24h,第2,3天雷莫司琼和格拉司琼对食欲不振、恶心和止吐作用的有效率相似,差异无显著性(P>0.05)。出现头痛、头重感、口干、便秘、腹泻、身体发热感、疲倦、嗜睡、失眠、焦躁不安等不良反应,其发生率两组比较未见显著性差异。结论:雷莫司琼作为新一代的高效高选择性5-HT_3受体拮抗剂,可以有效的拮抗化疗药物所引起的恶心、呕吐等反应,具有较好的使用安全性,可以广泛应用于临床。
Objective; To observe ramosetron's effects on prevention of gastrointestinal reactions induced by cisplatin and doxorubicin. Method: 156 cancer patients with an indication of intra-arterial chemotherapy were randomly divided into two groups, 78 cases each receiving cisplatin (≥50mg/m2) and doxorubicin (≥40 mg/m2) respectively in the therapy scheme. 15-30 minutes before chemotherapy group one was given with ramosetron 0.3mg and group two granisetron 3mg (plus dexam-ethasone10mg) by intravenous injection. The patients were monitored during the first three days for effects and unwanted reactions of the two drugs. Results; Compared with granisetron, ramosetron showed the same therapeutic effects on anorexia, nausea and vomiting. And no significant differences of adverse reactions were found in the two groups, such as headache, carebaria, thirst, constipation, diarrhea, hot flushes, fatigue, drowsiness, insommia and dysphoria. Conclusion; As a new generation of 5-HT3-receptor antagonist, ramosetron has proved to be safely used for its antiemetic properties in clinical practice.
出处
《药物不良反应杂志》
2003年第1期5-8,共4页
Adverse Drug Reactions Journal
